Physician profile
Beth E Killian
NPI 1659336923
$1,331.01
in general payments reported to CMS, 2019-2025
15 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $593 · 2023: $482 · 2024: $95.40 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $177.26 | 2022-2023 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $174.81 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $140.88 | 2022 | |
| Lilly USA, LLC | $138.85 | 2022-2023 | Jardiance |
| Gilead Sciences, INC. | $119.70 | 2023 | Epclusa |
| Otsuka America Pharmaceutical, INC. | $98.81 | 2023 | Nuedexta |
| Merck Sharp & Dohme LLC | $97.63 | 2025 | Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.40 | 2024 | Jardiance |
| Novo Nordisk INC | $76.29 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $63.09 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $47.04 | 2023 | Dupixent |
| Abbvie INC. | $46.15 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.49 | 2022 | |
| Pfizer INC. | $15.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Killian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.